

Press Release

Granules India, SERP Join Hands to Strengthen Breast Cancer Screening in Sangareddy

Hyderabad | January 28, 2026: Granules India Limited today signed a Memorandum of Understanding (MoU) with the Society for Elimination of Rural Poverty (SERP), Government of Telangana, to strengthen access to breast cancer screening and awareness among underprivileged women in rural areas of Sangareddy district. The initiative focuses on early detection and preventive healthcare by bringing organised screening services closer to communities with limited access to medical infrastructure.

As part of this collaboration, Granules India, through its healthcare partners, AIG Hospitals, Asian Medical Foundation and UC Breast Foundation, will conduct breast cancer screening and awareness camps in Sangareddy district using the *Breast Health Express*, a mobile screening unit designed to reach underserved communities.

The initiative will be led in the presence of key dignitaries including **Ms. Divya Devarajan, IAS, Chief Executive Officer, SERP; Ms P. Pravinya I.A.S, Collector & District Magistrate, Sangareddy; Mrs. Uma Chigurupati, Executive Director, Granules India Limited; and Dr. Pragnya Chigurupati Narra, Oncologist & Oncoplastic Surgeon at AIG Hospitals and Founder, UC Breast Foundation.**

SERP will play a critical role by leveraging its extensive grassroots presence and Self-Help Group (SHG) network to mobilise women, promote awareness on early detection, and maximise on-ground participation across rural areas.

Ms. Divya Devarajan, IAS, CEO, SERP, said, “Ensuring access to preventive healthcare for women in rural areas is a key priority for the Government of Telangana. SERP’s grassroots network enables us to reach women at the community level, and this partnership with Granules India will help strengthen awareness, participation and early screening for breast cancer. Such collaborations are critical to driving long-term health outcomes among underserved populations.”

Mrs. Uma Chigurupati, Executive Director, Granules India Limited, said, “At Granules, we are committed to extending the benefits of preventive healthcare to communities that need it the most. Through this collaboration with SERP and our healthcare partners, we aim to make breast cancer screening more accessible in rural areas, reinforce the importance of early detection, and contribute meaningfully to women’s health and well-being.”

Dr. Pragnya Chigurupati Narra, Oncologist & Oncoplastic Surgeon at AIG Hospitals and Founder, UC Breast Foundation, said, “Lack of access remains one of the biggest barriers to early breast cancer diagnosis among rural women. Partnerships like this reinforce our responsibility to improve access and ensure women receive the guidance and early detection support they need. The MoU with the Government of Telangana is a significant step forward and a strong validation of the work we have been doing to advance breast cancer screening and awareness.”

Since its inception in September 2024, Granules Breast cancer screening and awareness initiative has screened over 5000 women and reached out to thousands of women through awareness campaigns.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and Switzerland. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL. For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com.

Safe Harbor: This document is to provide general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and is based on estimates and should not be considered as a recommendation that any investor should subscribe/purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward- looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, the ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Media Contact:

Priyanka Chawla
Corporate Communications
priyanka.chawla@granulesindia.com